Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
09/2001
09/27/2001WO2001070233A2 Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof
09/27/2001WO2001070232A1 Protease inhibitors
09/27/2001WO2001070230A2 Compounds with 5-ht activity useful for controlling visual field loss
09/27/2001WO2001070229A1 Thrombin inhibitors
09/27/2001WO2001070223A1 Compounds with 5-ht2 and 5-ht1a agonist activity for treating glaucoma
09/27/2001WO2001070222A2 Compounds with 5-ht1a activity useful for treating disorders of the outer retina
09/27/2001WO2001070219A1 Method of preparing alkylated salicylamides via a dicarboxylate intermediate
09/27/2001WO2001070213A2 Bactericidal antimicrobial methods and compositions for use in treating gram positive infections comprising an antibiotic potentiator having acyl hydrazide oxy amide or 8-hydroxy quinoline structure
09/27/2001WO2001070199A1 Matrices containing nitric oxide donors and reducing agents and their use
09/27/2001WO2001070175A2 Osteocalcin promoter directed adenovirus replicaton for therapy
09/27/2001WO2001070174A2 Vegf-modulated genes and methods employing them
09/27/2001WO2001062705A8 Aminoalcohol derivatives
09/27/2001WO2001062234A8 Dosing regimen
09/27/2001WO2001060822A8 Amino acid derivatives and use thereof as nep, ace and ece inhibitors
09/27/2001WO2001032663A3 Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same
09/27/2001WO2001019973A3 Nicotinic acetylcholine receptor: alpha10 subunit
09/27/2001WO2001019829A3 Pyrazolopyrimidines as therapeutic agents
09/27/2001WO2001019794A3 Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents
09/27/2001WO2001019320A3 Phospholipid prodrugs of anti-proliferative drugs
09/27/2001WO2001017558A3 Novel uses of mammalian ccr6 receptors and related reagents
09/27/2001WO2001016296A3 Use of cytokines, cells, and mitogens to inhibit graft versus host disease
09/27/2001WO2001016170A3 Card proteins involved in cell death regulation
09/27/2001WO2001012606B1 Tetrahydroquinoline derivatives having retinoid-like biological activity
09/27/2001WO2001012127B1 TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR
09/27/2001WO2001010903A3 Proteases and protease inhibitors
09/27/2001WO2001000665A3 Inhibitors of memapsin 2 and use thereof
09/27/2001WO2000071148A3 Therapeutic uses of agents that modulate the activity of alpha-smooth muscle actin
09/27/2001WO2000061541A3 Pharmaceutical compounds
09/27/2001WO2000061537A3 Pharmaceutical compounds
09/27/2001WO2000059489A8 Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites
09/27/2001WO2000057837A8 Compositions and methods for effecting the levels of cholesterol
09/27/2001WO2000046386A9 Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
09/27/2001WO2000041707A3 USE OF $i(LACTOBACILLUS SALIVARIUS)
09/27/2001US20010025113 Nutrients, foods, drugs
09/27/2001US20010025108 Thrombosis diseases
09/27/2001US20010025106 Antiallergens, bronchodilator
09/27/2001US20010025057 Containing nitric oxide donar containing nitroglycerin, glycol dinitrate, isopropyl nitrate, glyceryl-1,3-dinitrate, glyceryl-1,2-dinitrate, butane-1,2,4-triol-trinitrate, erythrityl teteranitrate, pentaerithrityl tetetranitrate etc.
09/27/2001US20010025052 Novel nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same
09/27/2001US20010025041 Amidino protease inhibitors
09/27/2001US20010025040 Useful for treating allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis; nonsedating antihistamines or salts, leukotriene D4 antagonist or 5-lipoxygenase inhibitor or FLAP protein antagonist
09/27/2001US20010025035 Water soluble prodrugs of hindered alcohols
09/27/2001US20010025033 Uracil substituted at 5-position by C2-4 alkynyl used as inactivator of uracil reductase enzyme
09/27/2001US20010025029 Novel stromelysin inhibitors
09/27/2001US20010025026 Chimeric proteins for use in transport of a selected substance into cells
09/27/2001US20010024827 Which express a neuron-specific marker and which can give rise to progeny which can differentiate into neuronal cells; for treatment of neuronal disorders
09/27/2001US20010024824 Stem cells and their use in transplantation
09/27/2001US20010024664 Alzheimer's diseases; central nervous system disorders; antiinflammatory agent; solvent extraction from plants
09/27/2001US20010024658 A delayed release pharmaceutical dosage form for oral administration of heparin comprising a low molecular weight heparin, a bile salt or acid, and a surfactant selected from hydrophilc and lipophilic, and a means for sustained release
09/27/2001US20010024642 A chewing gum that includes a gum center and a coating that substantially surrounds the center, comprises at least 50% by weight of chewing gum, the coating includes medicine; chewing the gum, causes the drug release, in patients buccal cavity
09/27/2001DE10014645A1 New amidino-aryl substituted biphenyl derivatives and analogs as Factor Xa inhibitors, are useful for treating thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy or angina pectoris
09/27/2001DE10012120A1 New ligand, comprising therapeutic or diagnostic agent bonded non-covalently with substance having high affinity to transport molecule
09/27/2001CA2404275A1 Cosmetic use of hop and ornithine
09/27/2001CA2404260A1 Identification of essential genes in prokaryotes
09/27/2001CA2404226A1 Furoisoquinoline derivatives, process for producing the same and use thereof
09/27/2001CA2404216A1 Novel polypeptides, and nucleic acids encoding the same
09/27/2001CA2404206A1 Protease inhibitors
09/27/2001CA2404131A1 Heterocyclic side chain containing, n-substituted metalloprotease inhibitors
09/27/2001CA2404076A1 Heterocyclic side chain containing metalloprotease inhibitors
09/27/2001CA2404002A1 Inhibitors of histone deacetylase
09/27/2001CA2403828A1 Inhibitors of p38
09/27/2001CA2403823A1 Thioketals and thioethers for inhibiting the expression of vcam-1
09/27/2001CA2403818A1 Matrices containing nitric oxide donors and reducing agents and their use
09/27/2001CA2403809A1 Angiogenesis - associated proteins, and nucleic acids encoding the same
09/27/2001CA2403805A1 Amines substituted with a dihydronaphthalenyl, crhomenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
09/27/2001CA2403804A1 Vegf-modulated genes and methods employing them
09/27/2001CA2403795A1 Osteocalcin promoter directed adenovirus replicaton for therapy
09/27/2001CA2403778A1 Carbocyclic side chain containing metalloprotease inhibitors
09/27/2001CA2403669A1 Methods and reagents for regulation of cellular responses in biological systems
09/27/2001CA2403631A1 Spiropiperidine derivatives as melanocortin receptor agonists
09/27/2001CA2403558A1 Thrombin inhibitors
09/27/2001CA2403444A1 Restenosis treatment
09/27/2001CA2403436A1 Acute neuronal induced calcium binding protein type 1 ligand
09/27/2001CA2402836A1 Process for preparing crystalline form i of cabergoline
09/27/2001CA2402763A1 Proteases
09/27/2001CA2402747A1 G-protein associated molecules
09/27/2001CA2402722A1 Sperm factor oscillogenin
09/27/2001CA2402596A1 Anti-tissue factor antibodies with enhanced anticoagulant potency
09/27/2001CA2402414A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors
09/27/2001CA2401984A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors
09/27/2001CA2401959A1 5-hydroxy indazole derivatives for treating glaucoma
09/27/2001CA2401887A1 Nusap, a novel gene encoding a tissue-specific nuclear protein, useful as a diagnostic tool and therapeutic agent
09/27/2001CA2401870A1 Cyclic .beta.-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-.alpha.
09/27/2001CA2401749A1 Compounds and methods to treat alzheimer's disease
09/27/2001CA2401368A1 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
09/27/2001CA2400637A1 Compounds with 5-ht2 and 5-ht1a agonist activity for treating glaucoma
09/27/2001CA2400168A1 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
09/27/2001CA2400000A1 4-oxo-1,4-dihydro-3-cinnolinecarboxamides as antiviral agents
09/27/2001CA2399991A1 4-hydroxy-1,8-naphthyridine-3-carboxamides as antiviral agents
09/27/2001CA2399985A1 Compounds with 5-ht activity useful for controlling visual field loss
09/27/2001CA2364268A1 Di-substituted iminoheterocyclic compounds
09/26/2001EP1136571A2 Detection of polymorphisms in the MxA gene to predict the response of an hepatitis C virus infected individual to interferon therapy
09/26/2001EP1136567A1 Method and kit for the screening, the detection and /or the quantification of transcriptional factors
09/26/2001EP1136561A2 Targeting gene therapy
09/26/2001EP1136547A2 Adamts polypeptides, nucleic acids encoding them, and uses thereof
09/26/2001EP1136492A1 Sulfonamide compounds and uses thereof as medicines
09/26/2001EP1136488A1 Sf2809-i, ii, iii, iv, v and vi substances exhibiting chymase-inhibiting activities
09/26/2001EP1136482A1 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
09/26/2001EP1136479A1 Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease
09/26/2001EP1136475A1 Piperidine and piperazine compounds for use in the treatment of Alzheimer
09/26/2001EP1136474A1 1-Acetyl-5-bromo-4,6-dimethyl-indoline
1 ... 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 ... 1564